100 related articles for article (PubMed ID: 26585571)
21. Diisothiocyanate-Derived Mercapturic Acids Are a Promising Partner for Combination Therapies in Glioblastoma.
Xu P; Westhoff MA; Hadzalic A; Debatin KM; Winiarski L; Oleksyszyn J; Wirtz CR; Knippschild U; Burster T
ACS Omega; 2022 Feb; 7(7):5929-5936. PubMed ID: 35224353
[TBL] [Abstract][Full Text] [Related]
22. BH3-mimetics: recent developments in cancer therapy.
Townsend PA; Kozhevnikova MV; Cexus ONF; Zamyatnin AA; Soond SM
J Exp Clin Cancer Res; 2021 Nov; 40(1):355. PubMed ID: 34753495
[TBL] [Abstract][Full Text] [Related]
23. Crosstalk of the Wnt/β-Catenin Signaling Pathway in the Induction of Apoptosis on Cancer Cells.
Trejo-Solis C; Escamilla-Ramirez A; Jimenez-Farfan D; Castillo-Rodriguez RA; Flores-Najera A; Cruz-Salgado A
Pharmaceuticals (Basel); 2021 Aug; 14(9):. PubMed ID: 34577571
[TBL] [Abstract][Full Text] [Related]
24. Programmed cell death, redox imbalance, and cancer therapeutics.
Dai X; Wang D; Zhang J
Apoptosis; 2021 Aug; 26(7-8):385-414. PubMed ID: 34236569
[TBL] [Abstract][Full Text] [Related]
25. Reversing tozasertib resistance in glioma through inhibition of pyruvate dehydrogenase kinases.
Jane EP; Premkumar DR; Rajasundaram D; Thambireddy S; Reslink MC; Agnihotri S; Pollack IF
Mol Oncol; 2022 Jan; 16(1):219-249. PubMed ID: 34058053
[TBL] [Abstract][Full Text] [Related]
26. Cyclin-dependent kinase inhibitors exert distinct effects on patient-derived 2D and 3D glioblastoma cell culture models.
Riess C; Koczan D; Schneider B; Linke C; Del Moral K; Classen CF; Maletzki C
Cell Death Discov; 2021 Mar; 7(1):54. PubMed ID: 33723248
[TBL] [Abstract][Full Text] [Related]
27. Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors.
Floros KV; Jacob S; Kurupi R; Fairchild CK; Hu B; Puchalapalli M; E Koblinski J; Dozmorov MG; Boikos SA; Scaltriti M; Faber AC
Cell Death Dis; 2021 Feb; 12(2):179. PubMed ID: 33589591
[TBL] [Abstract][Full Text] [Related]
28. Single Agent and Synergistic Activity of Maritoclax with ABT-263 in Nasopharyngeal Carcinoma (NPC) Cell Lines.
Xiang BLS; Kwok-Wai L; Soo-Beng AK; Mohana-Kumaran N
Trop Life Sci Res; 2020 Oct; 31(3):1-13. PubMed ID: 33214852
[TBL] [Abstract][Full Text] [Related]
29. Cyclin-dependent kinase inhibitors in head and neck cancer and glioblastoma-backbone or add-on in immune-oncology?
Riess C; Irmscher N; Salewski I; Strüder D; Classen CF; Große-Thie C; Junghanss C; Maletzki C
Cancer Metastasis Rev; 2021 Mar; 40(1):153-171. PubMed ID: 33161487
[TBL] [Abstract][Full Text] [Related]
30. Significance of Targeting VEGFR-2 and Cyclin D1 in Luminal-A Breast Cancer.
Abdalla AN; Qattan A; Malki WH; Shahid I; Hossain MA; Ahmed M
Molecules; 2020 Oct; 25(20):. PubMed ID: 33050377
[TBL] [Abstract][Full Text] [Related]
31. Use of ratiometrically designed nanocarrier targeting CDK4/6 and autophagy pathways for effective pancreatic cancer treatment.
Ji Y; Liu X; Li J; Xie X; Huang M; Jiang J; Liao YP; Donahue T; Meng H
Nat Commun; 2020 Aug; 11(1):4249. PubMed ID: 32843618
[TBL] [Abstract][Full Text] [Related]
32. Targeting NAD
Jane EP; Premkumar DR; Thambireddy S; Golbourn B; Agnihotri S; Bertrand KC; Mack SC; Myers MI; Chattopadhyay A; Taylor DL; Schurdak ME; Stern AM; Pollack IF
Mol Cancer Res; 2020 Jul; 18(7):1004-1017. PubMed ID: 32238439
[TBL] [Abstract][Full Text] [Related]
33. G2/M inhibitors as pharmacotherapeutic opportunities for glioblastoma: the old, the new, and the future.
Castro-Gamero AM; Pezuk JA; Brassesco MS; Tone LG
Cancer Biol Med; 2018 Nov; 15(4):354-374. PubMed ID: 30766748
[TBL] [Abstract][Full Text] [Related]
34. Autophagic and Apoptotic Pathways as Targets for Chemotherapy in Glioblastoma.
Trejo-Solís C; Serrano-Garcia N; Escamilla-Ramírez Á; Castillo-Rodríguez RA; Jimenez-Farfan D; Palencia G; Calvillo M; Alvarez-Lemus MA; Flores-Nájera A; Cruz-Salgado A; Sotelo J
Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30486451
[TBL] [Abstract][Full Text] [Related]
35. Drug Repositioning in Glioblastoma: A Pathway Perspective.
Tan SK; Jermakowicz A; Mookhtiar AK; Nemeroff CB; Schürer SC; Ayad NG
Front Pharmacol; 2018; 9():218. PubMed ID: 29615902
[TBL] [Abstract][Full Text] [Related]
36. Chemical Genetic Screens Identify Kinase Inhibitor Combinations that Target Anti-Apoptotic Proteins for Cancer Therapy.
Contreras JI; Robb CM; King HM; Baxter J; Crawford AJ; Kour S; Kizhake S; Sonawane YA; Rana S; Hollingsworth MA; Luo X; Natarajan A
ACS Chem Biol; 2018 May; 13(5):1148-1152. PubMed ID: 29608269
[TBL] [Abstract][Full Text] [Related]
37. Synergistic anti-proliferative effects of combination of ABT-263 and MCL-1 selective inhibitor A-1210477 on cervical cancer cell lines.
Lian BSX; Yek AEH; Shuvas H; Abdul Rahman SF; Muniandy K; Mohana-Kumaran N
BMC Res Notes; 2018 Mar; 11(1):197. PubMed ID: 29580266
[TBL] [Abstract][Full Text] [Related]
38. Mitochondrial dysfunction RAD51, and Ku80 proteolysis promote apoptotic effects of Dinaciclib in Bcl-xL silenced cells.
Premkumar DR; Jane EP; Thambireddy S; Sutera PA; Cavaleri JM; Pollack IF
Mol Carcinog; 2018 Apr; 57(4):469-482. PubMed ID: 29240261
[TBL] [Abstract][Full Text] [Related]
39. Revisiting CDK Inhibitors for Treatment of Glioblastoma Multiforme.
Lubanska D; Porter L
Drugs R D; 2017 Jun; 17(2):255-263. PubMed ID: 28324583
[TBL] [Abstract][Full Text] [Related]
40. Survivin inhibitor YM155 induces mitochondrial dysfunction, autophagy, DNA damage and apoptosis in Bcl-xL silenced glioma cell lines.
Jane EP; Premkumar DR; Sutera PA; Cavaleri JM; Pollack IF
Mol Carcinog; 2017 Apr; 56(4):1251-1265. PubMed ID: 27805285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
